title: Parathyroid Allotransplant With a New Technique: A Prospective Clinical Trial.
abstract: OBJECTIVE
  Parathyroid allotransplant is a valuable alternative in treating permanent hypoparathyroidism. However, it is a difficult process that requires several trained staff and advanced laboratory equipment, which makes the costs high. Here, we identify a new parathyroid allotransplant technique.
  
  
  METHODS
  After obtaining informed consent from patients, parathyroid cell suspensions obtained from 4 donors who had undergone a subtotal parathyroidectomy owing to chronic renal failure were transplanted in 10 patients with permanent hypoparathyroidism after short-term cell cultivation. Prednisolone were used as immunosuppressant for the first 10 days and discontinued thereafter.
  
  
  RESULTS
  Allograft function was observed in 7 patients (70%) at a mean follow-up of 12 months. Daily oral calcium and vitamin D supplementations discontinued totally in 7 patients. No major or minor complication was observed.
  
  
  CONCLUSIONS
  Our technique is simple, fast, and has a low cost, with a 70% success rate at a mean follow-up of 12 months. It requires few staff, minimal equipment, and short-term immunosuppressant use for maintenance. The technical developments of parathyroid allotransplant, as mentioned in this study, may be important in treating permanent hypoparathyroidism.
authors.affiliation: From the Department of General Surgery, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey.
authors.forename: Erhan
authors.initials: E
authors.lastname: Aysan
authors.forename: Burcugul
authors.initials: B
authors.lastname: Altug
authors.forename: Cilem
authors.initials: C
authors.lastname: Ercan
authors.forename: Cemile
authors.initials: C
authors.lastname: Kesgin Toka
authors.forename: Ufuk Oguz
authors.initials: UO
authors.lastname: Idiz
authors.forename: Mahmut
authors.initials: M
authors.lastname: Muslumanoglu
mesh_terms: D000328:Adult; D064591:Allografts; D015415:Biomarkers / Q000097:blood; D017690:Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D002478:Cells, Cultured; D004334:Drug Administration Schedule; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007011:Hypoparathyroidism / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000601:surgery*; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008875:Middle Aged; D010280:Parathyroid Glands / Q000276:immunology / Q000378:metabolism / Q000637:transplantation*; D010281:Parathyroid Hormone / Q000097:blood; D016105:Parathyroidectomy / Q000009:adverse effects*; D011239:Prednisolone / Q000008:administration & dosage; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey; D055815:Young Adult
chemical_list: D015415:Biomarkers; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; C470125:PTH protein, human; D010281:Parathyroid Hormone; D011239:Prednisolone